Advanced Clear Cell Renal Cell Carcinoma Clinical Trial
Official title:
A Phase 2, Multicenter, Open-Label Study to Evaluate the Preliminary Efficacy and Safety of 6MW3211 in Patients With Advanced Clear Cell Renal Cancer
single arm, non-randomized, multicenter, open label, phase 2 clinical trial in patients with advanced clear cell renal cacer
This study is a single arm, non-randomized, multicenter, open label, phase 2 clinical trial to evaluate preliminary efficacy and safety in patients with advanced clear cell renal cacer ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05122546 -
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
|
Phase 1 | |
| Withdrawn |
NCT05176288 -
Avelumab, Palbociclib and Axitinib in Advanced RCC
|
Phase 2 | |
| Active, not recruiting |
NCT04904302 -
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
|
Phase 2 | |
| Recruiting |
NCT06399419 -
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
|
Phase 1 | |
| Recruiting |
NCT05012371 -
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
|
Phase 2 | |
| Recruiting |
NCT05361720 -
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
|
Phase 2 | |
| Terminated |
NCT03260504 -
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
|
Phase 1 |